Business Description
Cytokinetics Inc
NAICS : 325412
SIC : 2834
ISIN : US23282W6057
Share Class Description:
FRA:KK3A: Ordinary SharesTotal Employee Number:
673Description
Cytokinetics Inc is a late-stage biopharmaceutical company based in South San Francisco, California, focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as treatments for diseases in which muscle performance is compromised. Its pipeline targets cardiovascular and neuromuscular conditions, including hypertrophic cardiomyopathy, heart failure, amyotrophic lateral sclerosis, and spinal muscular atrophy. Aficamten, a cardiac myosin inhibitor, is its lead cardiovascular candidate for hypertrophic cardiomyopathy; omecamtiv mecarbil is a cardiac myosin activator; and reldesemtiv and other skeletal muscle activators target neuromuscular disorders. The company conducts clinical trials in the United States and internationally, often in collaboration with partners and academic centers. It has no significant marketed products and generates revenue primarily through research collaborations, licensing agreements, and milestone payments rather than product sales, while funding operations largely through equity financings and partnership proceeds.
Financial Strength
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.92 | |||||
Equity-to-Asset | -0.09 | |||||
Debt-to-Equity | -7.32 | |||||
Debt-to-EBITDA | -1.68 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | -0.54 | |||||
Beneish M-Score | -0.53 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -11.4 | |||||
3-Year EBITDA Growth Rate | -14.8 | |||||
3-Year EPS without NRI Growth Rate | -11.2 | |||||
3-Year FCF Growth Rate | -8.8 | |||||
3-Year Book Growth Rate | -67.7 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 31 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 121.53 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 35.18 | |||||
9-Day RSI | 37.73 | |||||
14-Day RSI | 39.17 | |||||
3-1 Month Momentum % | -4.81 | |||||
6-1 Month Momentum % | 19.44 | |||||
12-1 Month Momentum % | 57.32 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.66 | |||||
Quick Ratio | 6.66 | |||||
Cash Ratio | 6.43 | |||||
Days Inventory | 11.97 | |||||
Days Sales Outstanding | 63.91 | |||||
Days Payable | 948.96 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -9 | |||||
Shareholder Yield % | -4.42 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 87.97 | |||||
Operating Margin % | -1046.12 | |||||
Net Margin % | -1321.12 | |||||
EBITDA Margin % | -1118.12 | |||||
FCF Margin % | -848.9 | |||||
OCF Margin % | -811.9 | |||||
ROA % | -61.36 | |||||
ROIC % | -116.93 | |||||
3-Year ROIIC % | -73.24 | |||||
ROC (Joel Greenblatt) % | -503.46 | |||||
ROCE % | -59.83 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 129.86 | |||||
EV-to-EBIT | -12.7 | |||||
EV-to-Forward-EBIT | -14.95 | |||||
EV-to-EBITDA | -12.93 | |||||
EV-to-Forward-EBITDA | -14.95 | |||||
EV-to-Revenue | 144.52 | |||||
EV-to-Forward-Revenue | 21.83 | |||||
EV-to-FCF | -17.83 | |||||
Price-to-GF-Value | 0.32 | |||||
Price-to-Median-PS-Value | 4.01 | |||||
Earnings Yield (Greenblatt) % | -7.87 | |||||
FCF Yield % | -6.01 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Cytokinetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 58.073 | ||
| EPS (TTM) (€) | -6.191 | ||
| Beta | 1.3758 | ||
| 3-Year Sharpe Ratio | 0.5 | ||
| 3-Year Sortino Ratio | 1.61 | ||
| Volatility % | 66.54 | ||
| 14-Day RSI | 39.17 | ||
| 14-Day ATR (€) | 1.253722 | ||
| 20-Day SMA (€) | 62.274 | ||
| 12-1 Month Momentum % | 57.32 | ||
| 52-Week Range (€) | 40.4 - 75.62 | ||
| Shares Outstanding (Mil) | 139.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Cytokinetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Cytokinetics Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Annual report for 2026 | 2027-02-26 | In 157 days | ||
| Fourth quarter earnings conference call for 2026 | 2027-02-24 16:30 | In 156 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-24 16:00 | In 156 days | ||
| Third quarter earnings conference call for 2026 | 2026-11-05 16:30 | In 45 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 16:00 | In 45 days | ||
| Bernstein 3rd Annual Healthcare Forum | 2026-09-23 08:50 | In 2 days | ||
| Morgan Stanley 24th Annual Global Healthcare Conference | 2026-09-14 07:45 | 63.40 (+0.99%) | ||
| Guidance call for 2026 | 2026-09-10 11:30 | 63.20 (-1.10%) | ||
| Guidance call for 2026 | 2026-09-09 15:00 | 64.16 (+4.94%) | ||
| Second quarter earnings conference call for 2026 | 2026-08-06 16:30 | 67.44 (+0.00%) |
Show
Entries
Cytokinetics Inc Frequently Asked Questions
What is Cytokinetics Inc(FRA:KK3A)'s stock price today?
The current price of FRA:KK3A is €58.34. The 52 week high of FRA:KK3A is €75.62 and 52 week low is €40.40.
When is next earnings date of Cytokinetics Inc(FRA:KK3A)?
The next earnings date of Cytokinetics Inc(FRA:KK3A) is 2026-11-05 Est..
Does Cytokinetics Inc(FRA:KK3A) pay dividends? If so, how much?
Cytokinetics Inc(FRA:KK3A) does not pay dividend.
Press Release
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers